Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed, could worsen ...

Many investments Mr. Trump claims credit for predate his return to office or are based on vague future pledges. Here's a fact ...

One of the more interesting aspects about President Donald Trump's recent tariffs is that ... one of the best pharma stocks to own has been Eli Lilly (NYSE: LLY). But now, an investment in Lilly ...

Tariffs on pharmaceutical imports could hurt Lilly, especially with its dependence on products made in Ireland. The president ...

The president said his executive order will require pharmaceutical companies to price drugs in the U.S. in line with the ...

Ireland has become a major base for US pharma companies, including Pfizer, Eli Lilly and Johnson & Johnson. That’s bolstered the economies of individual towns and played a role in the country’s ...

Although AbbVie, Eli Lilly ... impact. Michaels noted "penalties in the government channel and with existing contracts in the commercial setting" as barriers to hiking drug prices. However, the ...

Johnson & Johnson factored roughly $400 million into its 2025 guidance to account for the impact ... the Trump administration could unleash an even bigger threat than tariffs to AbbVie, Lilly ...

President Trump recently warned big drugmakers that ... the president warned that a "tariff wall" is coming. Although AbbVie, Eli Lilly, and Johnson & Johnson manufacture many of their products ...